A Cohort Study of Hydatidiform Mole
ConditionHydatidiform Mole
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age13-55
SponsorWomen's Hospital School Of Medicine Zhejiang University
About this trial
The purpose of this study is to construct a cohort for the hydatidiform mole.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who are diagnosed with hydatidiform mole (including: complete hydatidiform mole/partial hydatidiform mole; one of twins with hydatidiform mole; ectopic pregnancy hydatidiform mole; macroscopic or microscopic hydatidiform changes indicating early complete or partial hydatidiform mole can not be excluded; atypical placental site nodule) for the first time;
Age 13-55 years old;
Obtain informed consent and sign an informed consent form
Disqualifiers
Patients who are unable to cooperate with the investigation such as mental disorders or cognitive impairment
No histopathology diagnosis;
Patients with other malignancies
Trial population
Outpatient or inpatient patients in women's hospital school medicine of zhejiang university and other cooperative hospitals (including tongji hosptial, tongji medical college of hust, qilu hosptial of shandong university, Sun Yat-sen university cancer center) were inclued in this cohort study if the patients met the eligibility requirements and agreed to participate in this study
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionThis is a prospective observational study with no intervention
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Malignant trophoblastic tumor
Patients with hydatidiform mole develop malignant trophoblastic tumor. The Federation of International of Gynecologists and Obstetricians criteria for diagnosis of postmolar gestational trophoblastic neoplasia were as follows: (1) when the plateau of human chorionic gonadotrophin (hCG) lasts for four measurements over a period of 3 weeks or longer; that is, days 1, 7, 14, 21; (2) when there is a rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; days 1, 7, 14; (3) If there is a histologic diagnosis of choriocarcinoma.
Time frame
4.5 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: